Scientists zoom in on bug behind
Strep throat and scarlet fever
Send a link to a friend
[May 28, 2019]
By Kate Kelland
LONDON, (Reuters) - Scientists studying a
bacterium that causes scarlet fever, severe sore throat and a form of
heart disease say they are closer to developing a vaccine that could one
day prevent hundred of thousands of infections a year.
|
In a study in the journal Nature Genetics, scientists from Britain
and Australia found detailed differences between strains of Group A
Streptococcus bacteria - known as Strep A - from 22 countries, but
also found several molecular targets common across many strains,
offering potential for vaccine development.
Strep A is one of the world's top 10 causes of death from infectious
diseases. It is estimated to cause more than half a million deaths
every year.
It can cause several different infections, ranging from Strep throat
to scarlet fever, which are constant threats in many parts of the
world, to an illness called rheumatic heart disease, which can
affect certain populations including Aboriginal Australians.
There is no effective vaccine for Strep A, and efforts to develop
one have been hampered by the huge number and variety of Strep A
strains - meaning it is very tricky to develop a vaccine that could
be effective against all of them.
In this work, researchers from Britain's Wellcome Sanger Institute
and Cambridge University, and from Australia's Doherty Institute and
Queensland University, sequenced the DNA of more than 2,000 Strep A
samples from 22 countries, including in Africa and from Australian
Aboriginal communities.
[to top of second column] |
"Using all the data we collected, we narrowed down common genes in
almost all strains of Strep A globally," said Mark Davies of the
Wellcome Sanger and Doherty institutes, who co-led the work.
"This is a tremendous step forward in identifying what may work as a
global vaccine candidate."
Mark Walker, director of the Australian Infectious Diseases Research
Centre, said the findings should "renew the momentum" and enable a
fast-track approach to a global Strep A shot since potential drug
developers could use the database to find the molecular targets most
likely to lead to an effective vaccine.
(Editing by Gareth Jones)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |